NRx Pharmaceuticals, Inc.
NRXP
$2.75
$0.124.56%
NASDAQ
| 06/30/2025 | 03/31/2025 | ||||
|---|---|---|---|---|---|
| Revenue | -- | -- | |||
| Total Other Revenue | -- | -- | |||
| Total Revenue | -- | -- | |||
| Cost of Revenue | -- | -- | |||
| Gross Profit | -- | -- | |||
| SG&A Expenses | -6.80% | 13.28% | |||
| Depreciation & Amortization | -- | -- | |||
| Other Operating Expenses | -- | -- | |||
| Total Operating Expenses | -0.45% | 3.11% | |||
| Operating Income | 0.45% | -3.11% | |||
| Income Before Tax | -218.96% | 39.28% | |||
| Income Tax Expenses | -- | -- | |||
| Earnings from Continuing Operations | -218.96% | 39.28% | |||
| Earnings from Discontinued Operations | -- | -- | |||
| Extraordinary Item & Accounting Change | -- | -- | |||
| Minority Interest in Earnings | -- | -- | |||
| Net Income | -218.96% | 39.28% | |||
| EBIT | 0.45% | -3.11% | |||
| EBITDA | 0.45% | -3.10% | |||
| EPS Basic | -191.84% | 54.67% | |||
| Normalized Basic EPS | -147.23% | 49.78% | |||
| EPS Diluted | -191.84% | 54.67% | |||
| Normalized Diluted EPS | -147.23% | 49.78% | |||
| Average Basic Shares Outstanding | 9.29% | 33.95% | |||
| Average Diluted Shares Outstanding | 9.29% | 33.95% | |||
| Dividend Per Share | -- | -- | |||
| Payout Ratio | -- | -- | |||